CD137 Is Induced by the CD40 Signal on Chronic Lymphocytic Leukemia B Cells and Transduces the Survival Signal via NF-κB Activation

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Nakaima, Yukana ^a   Watanabe, Ken ^a   Koyama, Takatoshi ^a   Miura, Osamu ^a   Fukuda, Tetsuya ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; PROTEIN P52;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD137; ANTIGENS, CD40; B-LYMPHOCYTES; CD40 LIGAND; CELL LINE; CELL LINE, TUMOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NF-KAPPA B; NF-KAPPA B P52 SUBUNIT;

EID: 84877816545     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064425     Document Type: Article

References (38)

1. Watts T, (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23: 23-68.
2. Wilcox R, Tamada K, Flies D, Zhu G, Chapoval A, et al. (2004) Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. Blood 103: 177-184.
3. Lynch D, (2008) The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 222: 277-286.
4. Lin W, Voskens C, Zhang X, Schindler D, Wood A, et al. (2008) Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies. Blood 112: 699-707.
5. Jiang D, Chen Y, Schwarz H, (2008) CD137 induces proliferation of murine hematopoietic progenitor cells and differentiation to macrophages. J Immunol 181: 3923-3932.
6. Jiang D, Yue P, Drenkard D, Schwarz H, (2008) Induction of proliferation and monocytic differentiation of human CD34+ cells by CD137 ligand signaling. Stem Cells 26: 2372-2381.
7. Lee S, Park Y, So T, Kwon B, Cheroutre H, et al. (2008) Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol 9: 917-926.
8. Lippert U, Zachmann K, Ferrari D, Schwarz H, Brunner E, et al. (2008) CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response. Eur J Immunol 38: 1024-1032.
9. Choi B, Kim Y, Kwon P, Lee S, Kang S, et al. (2009) 4-1BB functions as a survival factor in dendritic cells. J Immunol 182: 4107-4115.
10. Melero I, Murillo O, Dubrot J, Hervás-Stubbs S, Perez-Gracia J, (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 29: 383-390.
11. Olofsson P, Söderström L, Wågsäter D, Sheikine Y, Ocaya P, et al. (2008) CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 117: 1292-1301.
12. Jong D, Fest T, (2011) The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 24: 135-146.
13. Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159-2169.
14. Caligaris-Cappio F, Ghia P, (2008) Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 26: 4497-4503.
15. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
16. Dicker F, Kater A, Fukuda T, Kipps T, (2005) Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood 105: 3193-3198.
17. Dicker F, Kater A, Prada C, Fukuda T, Castro J, et al. (2006) CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 108: 3450-3457.
18. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 105: 3047-3052.
19. Endo T, Nishio M, Enzler T, Cottam H, Fukuda T, et al. (2007) BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 109: 703-710.
20. Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, et al. (2012) 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol 42: 737-748.
21. Setareh M, Schwarz H, Lotz M, (1995) A mRNA variant encoding a soluble form of 4-1BB, a member of the murine NGF/TNF receptor family. Gene 164: 311-315.
22. Michel J, Langstein J, Hofstädter F, Schwarz H, (1998) A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 28: 290-295.
23. Lee H, Park S, Choi B, Kim H, Nam K, et al. (2002) 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 169: 4882-4888.
24. Sabbagh L, Pulle G, Liu Y, Tsitsikov E, Watts T, (2008) ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol 180: 8093-8101.
25. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, et al. (2005) c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106: 1382-1391.
26. Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, et al. (2010) CD137 promotes proliferation and survival of human B cells. J Immunol 184: 787-795.
27. Scielzo C, Apollonio B, Scarfò L, Janus A, Muzio M, et al. (2011) The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia 25: 1760-1767.
28. Furtner M, Straub R, Krüger S, Schwarz H, (2005) Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia 19: 883-885.
29. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, et al. (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17: 515-524.
30. Claudio E, Brown K, Park S, Wang H, Siebenlist U, (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3: 958-965.
31. Coope H, Atkinson P, Huhse B, Belich M, Janzen J, et al. (2002) CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 21: 5375-5385.
32. Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, et al. (2007) Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 109: 1660-1668.
33. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, et al. (2008) c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 112: 5141-5149.
34. Ramsay A, Johnson A, Lee A, Gorgün G, Le Dieu R, et al. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118: 2427-2437.
35. Mellstedt H, Choudhury A, (2006) T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 55: 210-220.
36. Fayad L, Keating M, Reuben J, O'Brien S, Lee B, et al. (2001) Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97: 256-263.
37. Lotz M, Ranheim E, Kipps T, (1994) Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 179: 999-1004.
38. Houot R, Goldstein M, Kohrt H, Myklebust J, Alizadeh A, et al. (2009) Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 114: 3431-3438.